Skin bacteria could hold the key to safe treatments for eczema, new research suggests. A study led by scientists at The University of Manchester and Tokyo University of Agriculture and Technology found that harmless microbes living on our skin release powerful molecules, shutting down inflammation triggered by Staphylococcus… Read More
The University of Liverpool’s spin-out company, Galytx, has signed an exclusive licensing agreement with dermatology biotech Quodria. Together the companies plan to develop a first-in-class treatment for atopic dermatitis (AD), a form of eczema. Galytx, launched in June 2024, focuses on the development of galectin-3… Read More
DDW Editor Reece Armstrong speaks to Dr Steven Powell, co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Spun-out of the Univeristy of Dundee in… Read More
News round-up for 12-16 September by DDW Digital Content Editor Diana Spencer A slightly quieter week for news in light of national events in the UK, but the vital work of the international drug discovery community goes on and new discoveries are being made all the time. … Read More
A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal… Read More
